What is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and commercialization of novel therapeutics. The company specializes in addressing complex cardiovascular, metabolic, and liver-related conditions. Its primary asset, MGL-3196, represents a significant innovation in the field as an orally administered, liver-directed, thyroid hormone receptor-selective agonist. Currently undergoing Phase II clinical trials, this candidate targets non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia, positioning the company at the forefront of metabolic medicine. The firm's strategic focus on high-unmet-need indications allows it to maintain a distinct competitive advantage within the life sciences sector.
How much funding has Madrigal Pharmaceuticals raised?
Madrigal Pharmaceuticals has raised a total of $562.4M across 4 funding rounds:
Debt
$3.4M
Multiple Rounds
$559M
Debt (2016): $3.4M, investors not publicly disclosed
Debt (2022): $250M led by Hercules Capital
Stock Issuance/Offering (2022): $259M, investors not publicly disclosed
Debt (2022): $50M featuring Hercules Capital
Key Investors in Madrigal Pharmaceuticals
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Madrigal Pharmaceuticals?
Looking ahead, the strategic deployment of the $259M will be instrumental in scaling clinical operations and preparing for potential regulatory submissions. The company is expected to prioritize the advancement of its THR-selective agonist platform, potentially expanding its therapeutic reach into broader metabolic indications. Investors and stakeholders are closely monitoring the Phase II data readouts, which will serve as a primary catalyst for future valuation growth. As the company transitions from a development-focused entity to a potential commercial-stage powerhouse, the focus will likely shift toward manufacturing scalability and market access strategies for its lead therapeutic candidates.
See full Madrigal Pharmaceuticals company page
